Text Size
Santen Global

Press Release

Press Release

Launch of Aflibercept kit for IVT inj. 40 mg/mL Bayer
Santen Launches Verkazia® (Ciclosporin Eye Drops (III) ) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults
Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List
Santen and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases
Santen Launches SETANEO® Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension
Santen Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea
Announcement Regarding the Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
Santen Launches Global Employee Volunteer Initiative on World Sight Day — Responding to 167 Calls from Visually Impaired Individuals in 26 Languages via the Be My Eyes App —
Santen and RemeGen Announce Biologic License Application (BLA) Acceptance for RC28-E Intravitreal Injection in Diabetic Macular Edema in China
Santen Publishes its Annual Integrated Report “Santen Report 2025”
Notice of Corporate Officer Changes
Santen Launches TAPCOM® in China for Patients with Open-Angle Glaucoma or Ocular Hypertension
Santen Obtains Manufacturing and Marketing Approval in Japan for SETANEO® 0.002% Ophthalmic Solution, a Bicyclic Prostaglandin Derivative that Acts on FP and EP3 Receptors, for Treatment of Glaucoma and Ocular Hypertension
Santen Announces New Licensing Agreement with RemeGen for RC28-E Intravitreal Injection, an Anti-VEGF/FGF Dual-Target Fusion Protein
Back to News List
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved